|
Recent Developments |
|
12-NOV-14
Venus Remedies, a research based pharmaceutical company, has achieves yet another landmark by receiving marketing authorization in Switzerland through its German subsidiary Venus Pharma GmbH from Swiss drug authority (SWISSMEDIC) for its generic product Meropenem 500 mg & 1 g injection.
25-SEP-14
Venus Remedies has entered Singapore's topical pain management market with a marketing authorisation and patent for its herbal nanotechnolo... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015(12) | 31-Mar-2014 (12) | | Net sales | 3969.84 | 4497.45 | 5186.90 | | Other Income | 6.65 | 5.46 | 4.06 | | Total Income | 3976.49 | 4502.91 | 5190.96 | | Cost of goods sold | 3231.50 | 3649.42 | 3928.27 | | OPBDIT | 744.99 | 853.49 | 1262.69 | | PAT | 11.94 | 20.35 | 609.50 | | Gross Block | - | - | - | | Equity capital | 114.42 | 114.42 | 114.42 | | EPS (Rs.) | - | - | 54.19 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | 2.58 - 6.61 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 18.7 | 19.0 | 24.3 | | Net margin (% of OI) | 0.3 | 0.5 | 11.7 |
|
|
Detailed Financials
|
|
|
|
|
